Chemoembolization for treatment of hepatocellular carcinoma: national registry-based analysis

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14110%2F19%3A00110836" target="_blank" >RIV/00216224:14110/19:00110836 - isvavai.cz</a>

Result on the web

<a href="https://link.springer.com/content/pdf/10.1007/s00270-019-02282-x.pdf" target="_blank" >https://link.springer.com/content/pdf/10.1007/s00270-019-02282-x.pdf</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1007/s00270-019-02282-x" target="_blank" >10.1007/s00270-019-02282-x</a>

Result language

angličtina

Original language name

Chemoembolization for treatment of hepatocellular carcinoma: national registry-based analysis

Original language description

Purpose: To evaluate survival beneft in patient undergoing transarterial chemoembolization for hepatocellular carcinoma by national registry data analysis and comparison of regions with unequal usage of interventional radiology procedures. Material and methods: 4343 patients with primary diagnosis of HCC between 2010-2016 were extracted from the databases of The Czech National Cancer Registry. The analysis was supported by data from the National Registry of Paid Health Services and the Death Records Database. Primary treatment option was categorized as liver resection, ablation, TACE and chemotherapy. The regional data analysis provided information of IR procedures frequency for primary treatment of HCC. The 14 main regions were symmetrically divided to group with welldeveloped IR service and low-developed IR service according to the frequency of stage-adjusted IR procedure usage (&lt;15%,&gt;15%). Kaplan-Meier and Cox regression were used for survival and hazard ratios analyses. Results: Only 1730 patients had assessed any primary treatment option, 16.5% (285) were treated by TACE. Median of survival were signifcantly diferent in regions with well and low developed IR service for whole study population (13.2 months vs 6.5, p&lt; 0.001), patients treated in regions with well developed IR service had lower risk of death during treatment (HR=0.73 (0.66-0.81). The patient treated by TACE had median of survival 15.8 months (13.5-18.1), while the survival was not signifcantly diferent in region groups. Conclusion: The usage of anticancer therapies based on IR procedures is a huge factor infuencing the survival of HCC patient according to population-based data. Studies gathering data from cancer register databases can provide further information on treatment efectiveness.

Czech name

—

Czech description

—

Type

O - Miscellaneous

CEP classification

—

OECD FORD branch

30224 - Radiology, nuclear medicine and medical imaging

Project

—

Continuities

S - Specificky vyzkum na vysokych skolach

Publication year

2019

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů